A Phase 2 interventional study of LNA043 and placebo to LNA043 in Knee Cartilage Lesion, sponsored by Novartis Pharmaceuticals. Terminated at 2 sites in Austria. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2021-10-07.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to assess safety, tolerability, pharmacokinetics and preliminary efficacy of a single intra-articular (i.a.) administration of LNA043 in regenerating the articular cartilage of the knee, in a standardized clinical scenario of acute cartilage defect. The study aimed at characterizing the mechanism of action of LNA043
This was a non-confirmatory, patient and investigator blinded, randomized, placebo-controlled, parallel group, single dose study in patients with cartilage lesions undergoing autologous cartilage implantation (ACI). Participants were treated only on one occasion (Day 1) with a single i.a. injection that was performed under arthroscopic visualization and followed up for 28 weeks.
Originally approximately 22 patients were planned to be enrolled in two cohorts (LNA043 20 mg and LNA043 40 mg). The study was terminated before any patient was randomized into the LNA043 40 mg cohort
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LNA043 20mg/ml single dose
Biological: LNA043
Matching placebo to 20mg/3ml, single dose
Biological: placebo to LNA043
LNA043 40mg/ml single dose
Biological: LNA043
Matching placebo to 40mg/4ml, single dose
Biological: placebo to LNA043
LNA043 Single dose
placebo to LNA043 single dose
Change From Baseline in GAG Content
Sodium MRI-based measurements of change from baseline in glycosaminoglycan (GAG) content were assessed from both defective sites and a nearby healthy cartilage region (as a reference tissue). Specifically, the ratio of normalized sodium signal in the surgically created defect (SCD or donor site) to healthy non-weight bearing region (HNWB), i.e. SCD/HNWB and the defect to be treated (DTBT or main lesion) to healthy weight bearing region (HWB), i.e. DTBT/HWB was of major interest
Time frame: Baseline, Week 4
Bi-layer Collagen Organization Based on MRI Measurements
MRI T2 maps were generated and zonal T2 ratios (superficial layer T2 / deep layer T2) were calculated to assess the collagen fiber organization in the surgically created defect (SCD) and defect to be treated (DTBT) cartilage regions.
Time frame: Week 4
Change From Baseline in International Cartilage Repair Society (ICRS) Scoring
Extent of the repair tissue at the donor site before surgery. Each criterion was evaluated based on the visual analog scale and graded from 0 (best) to 100 (worst).
Time frame: Week 4
Percentage of Donor Site Refilling Based on MRI Measurements.
Extent of filling of the donor site over a longer term. Percentage change from baseline in refilling of cartilage defect based on 7T MRI for donor Region.
Time frame: Baseline, Week 4, Week 12 and Week 28
Change From Baseline in GAG Content
Sodium MRI-based measurements of change from baseline in glycosaminoglycan (GAG) content was assessed from both defective sites and a nearby healthy cartilage region (as a reference tissue). Specifically, the ratio of normalized sodium signal in the surgically created defect (SCD or donor site) to healthy non-weight bearing region (HNWB), i.e. SCD/HNWB was of major interest
Time frame: Baseline, Week 12 and Week 28
Bi-layer Collagen Organization Based on MRI Measurements
MRI T2 maps were generated and zonal T2 ratios (superficial layer T2 / deep layer T2) were calculated to assess the collagen fiber organization in the SCD cartilage region.
Time frame: Week 12 and Week 28
PK Profile of LNA043 and of AngPTL3 in Serum Cmax
Local and systemic pharmacokinetics (PK) of LNA043 following a single i.a. administration
Time frame: 4 weeks
PK Profile of LNA043 and of AngPTL3 in Serum AUC
Local and systemic pharmacokinetics (PK) of LNA043 following a single i.a. administration
Time frame: 4 weeks
Number of Participants With Anti-LNA043 Antibodies in Serum
Potential immunogenicity of LNA043
Time frame: Baseline, Week 1, Week 4, Week 12 and Week 28
All patients were recruited from 3 clinical sites in Austria.
| Milestone | LNA043 20mg | Matching Placebo to 20mg | LNA043 40mg | Matching Placebo to 40mg |
|---|---|---|---|---|
| Started | 9 | 5 | 0 | 0 |
| Completed | 9 | 5 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
Sodium MRI-based measurements of change from baseline in glycosaminoglycan (GAG) content were assessed from both defective sites and a nearby healthy cartilage region (as a reference tissue). Specifically, the ratio of normalized sodium signal in the surgically created defect (SCD or donor site) to healthy non-weight bearing region (HNWB), i.e. SCD/HNWB and the defect to be treated (DTBT or main lesion) to healthy weight bearing region (HWB), i.e. DTBT/HWB was of major interest
| Ratio | LNA043 20mg | Matching Placebo to 20mg |
|---|---|---|
| SCD/HNWB | 0.24 ± 0.06 | 0.06 ± 0.12 |
| DTBT/HWB | 0.08 ± 0.04 | 0.09 ± 0.09 |
MRI T2 maps were generated and zonal T2 ratios (superficial layer T2 / deep layer T2) were calculated to assess the collagen fiber organization in the surgically created defect (SCD) and defect to be treated (DTBT) cartilage regions.
| Ratio | LNA043 20mg | Matching Placebo to 20mg |
|---|---|---|
| Bi-layer Collagen Organization Based on MRI Measurements | 1.01 ± 0.07 | 0.95 ± 0.09 |
Extent of the repair tissue at the donor site before surgery. Each criterion was evaluated based on the visual analog scale and graded from 0 (best) to 100 (worst).
| Unit on a scale | LNA043 20mg | Matching Placebo to 20mg |
|---|---|---|
| Abnormal Calcification/Ossification | 98.75 ± 1.05 | 100.00 ± 1.48 |
| Cell Morphology | 61.43 ± 14.14 | 56.67 ± 21.60 |
| Chondrocyte clustering | 85.71 ± 8.37 | 85.00 ± 12.78 |
| Inflammation | 92.50 ± 2.15 | 98.75 ± 3.04 |
| Matrix Staining | 57.14 ± 12.17 | 25.00 ± 18.59 |
| Overall assessment | 49.29 ± 12.23 | 55.00 ± 18.68 |
| Tissue Morphology | 71.43 ± 7.78 | 65.00 ± 11.88 |
| Vascularisation in repaired tissue | 66.25 ± 12.88 | 77.50 ± 18.21 |
| Basal Integration | 82.86 ± 10.64 | 90.00 ± 16.26 |
| Formation of a Tidemark | 65.71 ± 18.15 | 63.33 ± 27.72 |
| Mid/Deep zone assessment | 50.00 ± 14.56 | 56.67 ± 22.24 |
| Subcondral bone abnormalities/marrow fibrosis | 73.75 ± 13.45 | 77.50 ± 19.01 |
| Surface Architecture | 57.86 ± 11.33 | 80.00 ± 17.31 |
| Surface/Superficial assessment | 56.43 ± 11.42 | 83.33 ± 17.44 |
Extent of filling of the donor site over a longer term. Percentage change from baseline in refilling of cartilage defect based on 7T MRI for donor Region.
| Percent | LNA043 20mg | Matching Placebo to 20mg |
|---|---|---|
| Week 4 | 64.38 ± 7.80 | 38.15 ± 11.03 |
| Week 12 | 60.25 ± 14.55 | 32.44 ± 19.09 |
| Week 28 (EOS) | 86.53 ± 11.09 | 62.73 ± 14.52 |
Sodium MRI-based measurements of change from baseline in glycosaminoglycan (GAG) content was assessed from both defective sites and a nearby healthy cartilage region (as a reference tissue). Specifically, the ratio of normalized sodium signal in the surgically created defect (SCD or donor site) to healthy non-weight bearing region (HNWB), i.e. SCD/HNWB was of major interest
| Ratio | LNA043 20mg | Matching Placebo to 20mg |
|---|---|---|
| SCD/HNWB - Week 12 | 0.14 ± 0.07 | 0.15 ± 0.09 |
| SCD/HNWB - Week 28 | 0.33 ± 0.10 | 0.14 ± 0.14 |
MRI T2 maps were generated and zonal T2 ratios (superficial layer T2 / deep layer T2) were calculated to assess the collagen fiber organization in the SCD cartilage region.
| Ratio | LNA043 20mg | Matching Placebo to 20mg |
|---|---|---|
| Week 12 | 1.44 ± 0.15 | 1.57 ± 0.18 |
| Week 28 | 1.33 ± 0.11 | 1.45 ± 0.14 |
Local and systemic pharmacokinetics (PK) of LNA043 following a single i.a. administration
| ng/mL | LNA043 20mg | Matching Placebo to 20mg |
|---|---|---|
| LNA043 | 57.4 ± 22.1 | — |
| AngPTL3 | 22.9 ± 9.03 | 26.6 ± 7.62 |
Local and systemic pharmacokinetics (PK) of LNA043 following a single i.a. administration
| hr*ng/mL | LNA043 20mg | Matching Placebo to 20mg |
|---|---|---|
| LNA043 | 821 ± 349 | — |
| AngPTL3 | 3130 ± 1440 | 3030 ± 1060 |
Potential immunogenicity of LNA043
| Participants | LNA043 20mg | Matching Placebo to 20mg |
|---|---|---|
| Day 1: anti-LNA043 antibodies present — YES | 0 | 0 |
| Day 1: anti-LNA043 antibodies present — NO | 9 | 5 |
| Day 8: anti-LNA043 antibodies present — YES | 0 | 0 |
| Day 8: anti-LNA043 antibodies present — NO | 9 | 5 |
| Day 29: anti-LNA043 antibodies present — YES | 0 | 0 |
| Day 29: anti-LNA043 antibodies present — NO | 9 | 5 |
| Day 85: anti-LNA043 antibodies present — YES | 0 | 0 |
| Day 85: anti-LNA043 antibodies present — NO | 9 | 5 |
| Day 197: anti-LNA043 antibodies present — YES | 0 | 0 |
| Day 197: anti-LNA043 antibodies present — NO | 9 | 5 |
Collected over Adverse events were collected from the dose of study treatment until up to 28 weeks post treatment. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LNA043 20mg | 0/9 (0%) | 0/9 (0%) | 4/9 (44.4%) |
| Placebo | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Event | LNA043 20mg | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 0/9 | 2/5 |
| HeadacheNervous system disorders | 2/9 | 0/5 |
| Thyroid massEndocrine disorders | 0/9 | 1/5 |
| NasopharyngitisInfections and infestations | 0/9 | 1/5 |
| Urinary tract infectionInfections and infestations | 0/9 | 1/5 |
| Joint range of motion decreasedMusculoskeletal and connective tissue disorders | 0/9 | 1/5 |
| VertigoEar and labyrinth disorders | 1/9 | 0/5 |
| Influenza like illnessGeneral disorders | 1/9 | 0/5 |
| ContusionInjury, poisoning and procedural complications | 1/9 | 0/5 |
| FallInjury, poisoning and procedural complications | 1/9 | 0/5 |
| Age, Continuous(years) | LNA043 20mg | Matching Placebo to 20mg | Total |
|---|---|---|---|
| Mean | 31.0 ± 6.16 | 39.4 ± 7.40 | 34.0 ± 7.60 |
| Sex: Female, Male(Participants) | LNA043 20mg | Matching Placebo to 20mg | Total |
|---|---|---|---|
| Female | 3 | 5 | 8 |
| Male | 6 | 0 | 6 |
| Race/Ethnicity, Customized(Participants) | LNA043 20mg | Matching Placebo to 20mg | Total |
|---|---|---|---|
| White | 9 | 5 | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Oct 2017 to primary completion in Apr 2019, 17 months.
Results were first posted in Apr 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LNA043